Palomar projects $10-15 mil. in Epilaser sales for remainder of 1996.
This article was originally published in The Gray Sheet
Executive Summary
PALOMAR EPILASER WILL GENERATE $10-15 MIL. IN REVENUE by the end of calendar 1996, Chairman and CEO Steven Georgiev said at a July 15 investor conference held in New York City. FDA cleared the firm's 510(k) on July 12 for a broad range of dermatological applications such as the removal of pigmented lesions, tattoos, skin lesions and birth marks.